Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity

This review examines the effects of psilocybin, the active compound in psychedelic mushrooms, on brain health. Psilocybin influences neurotransmitters like serotonin, reduces neuroinflammation, and promotes neuroplasticity—key factors in mental health disorders like depression and anxiety. Research suggests that both high-dose and microdosed psilocybin can improve mood, reduce anxiety, and alter brain network activity. While large-dose studies show strong therapeutic potential, microdosing remains controversial due to limited clinical evidence. Psilocybin's ability to regulate inflammation may have broader applications for mental and neurological conditions.

Supporting brain health involves managing inflammation and promoting neuroplasticity. Regular aerobic exercise, meditation, and a diet rich in antioxidants (e.g., leafy greens, nuts, and fish) help regulate neurotransmitters and reduce chronic stress. While psilocybin may offer therapeutic potential, robust clinical trials are needed. Individuals seeking cognitive benefits should prioritize evidence-backed interventions like good sleep hygiene and social engagement before considering emerging psychedelic therapies.